Answers are grounded in this paper and cite their sources.
Case report reveals thrombocytopenia in osteoporosis treatment with denosumab, indicating need for monitoring.
Denosumab has been widely utilized in the management of osteoporosis; however, thrombocytopenia as an adverse reaction associated with denosumab has been infrequently reported, and its underlying mechanism is not yet fully understood. We present a retrospective analysis of a rare case of suspected immune-mediated thrombocytopenia resembling immune thrombocytopenia (ITP) in a patient with primary osteoporosis following denosumab treatment, along with a comprehensive review of the relevant literature to investigate the potential mechanisms of denosumab-induced ITP-like thrombocytopenia. This case underscores the need for routine platelet monitoring during clinical use of denosumab and serves as a pharmacovigilance signal, providing a basis for future drug safety assessments.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: